BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 18467844)

  • 1. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
    Guidi E; Uboldi C; Ferretti L
    Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
    Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
    BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome aberrations in cattle with chronic enzootic haematuria.
    Lioi MB; Barbieri R; Borzacchiello G; Dezzi S; Roperto S; Santoro A; Russo V; Roperto F
    J Comp Pathol; 2004; 131(2-3):233-6. PubMed ID: 15276863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
    Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
    Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
    Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
    Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 intronic mutations in bovine enzootic hematuria-associated urinary bladder tumors.
    Sasani F; Baghban F; Nikbakht Brujeni GH; Kazemi M
    Vet Pathol; 2013 May; 50(3):543-7. PubMed ID: 23242803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
    Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
    Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
    Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
    Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
    J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semi-nested PCR for detection and typing of bovine Papillomavirus type 2 in urinary bladder and whole blood from cattle with enzootic haematuria.
    Wosiacki SR; Barreiro MA; Alfieri AF; Alfieri AA
    J Virol Methods; 2005 Jun; 126(1-2):215-9. PubMed ID: 15847940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fragile Histidine Triad gene and breast cancer.
    Yang Q; Yoshimura G; Sakurai T; Kakudo K
    Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of FHIT transcripts in normal and malignant breast tissue.
    Bièche I; Latil A; Becette V; Lidereau R
    Genes Chromosomes Cancer; 1998 Dec; 23(4):292-9. PubMed ID: 9824201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
    Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
    Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of the common fragile site FRA3B does not affect FHIT expression.
    Michael D; Rajewsky MF
    Oncogene; 2001 Mar; 20(14):1798-801. PubMed ID: 11313927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.